Breast Cancer Medical Services in China

Breast cancer is a malignant neoplasm originating in the mammary gland epithelium, most commonly ductal or lobular carcinoma. It remains the most frequently diagnosed malignancy among women globally, with incidence rising in both developed and emerging economies. Risk factors include genetic predisposition (e.g., BRCA1/BRCA2 pathogenic variants), hormonal exposure, lifestyle factors, and advancing age. Diagnosis relies on multimodal assessment: clinical breast examination, mammography, ultrasound, MRI, and image-guided core needle biopsy for histopathological and molecular profiling—including ER/PR status, HER2 expression, and Ki-67 index—to guide risk stratification and therapeutic decisions. Treatment is highly individualized, integrating surgery (lumpectomy or mastectomy), radiation oncology, systemic therapies (endocrine therapy, chemotherapy, targeted agents like CDK4/6 inhibitors or antibody-drug conjugates), and immunotherapy where indicated.

China offers compelling advantages for international patients seeking breast cancer care. The country hosts nationally accredited cancer centers—many affiliated with top-tier universities—with oncologists trained internationally and experienced in complex cases, including neoadjuvant strategies and fertility-preserving approaches. Advanced technologies such as digital breast tomosynthesis, intraoperative radiotherapy (IORT), robotic-assisted surgery, and next-generation sequencing for genomic profiling are widely available. Five-year relative survival rates for early-stage disease exceed 90% in leading institutions, supported by robust clinical trial participation and multidisciplinary tumor boards. Crucially, high-quality care is delivered at approximately 30–50% of costs in the US or Western Europe—without compromising evidence-based protocols or accreditation standards.

As a dedicated medical tourism agency, we facilitate seamless access to these resources for international patients: vetting JCI-accredited or NMPA-certified hospitals, coordinating specialist consultations, clarifying all-inclusive pricing upfront, arranging visas and accommodation, and providing bilingual clinical liaison and post-treatment follow-up support—all tailored to alleviate logistical and financial uncertainty.

Treatment Options & Itemized Cost Breakdown: Breast Cancer (Oncology Department)

Non-Surgical / Systemic Therapy Options

*Eligibility*: Confirmed invasive carcinoma or high-risk DCIS; biomarker testing required (ER/PR/HER2/Ki-67).

• •Endocrine Therapy (e.g., Tamoxifen, Letrozole, Anastrozole)

- *Criteria*: ER+/PR+ tumors, postmenopausal (aromatase inhibitors) or premenopausal (tamoxifen ± ovarian suppression)

- *Cost (3-month supply)*: - Generic tamoxifen: $18–$24 - Brand-name letrozole (Femara®): $120–$150 - Gonadotropin-releasing hormone agonist (e.g., goserelin): $280–$350/dose (monthly)

• •Anti-HER2 Targeted Therapy

- *Criteria*: HER2-positive (IHC 3+ or FISH-amplified)

- *Trastuzumab (IV, 6 mg/kg weekly × 12 weeks → 6 mg/kg q3w × 9 months)*: $2,100–$2,600/course - *Pertuzumab + trastuzumab + docetaxel (neoadjuvant)*: $4,800–$5,900/cycle (3 cycles)

• •Chemotherapy (Adjuvant/Neoadjuvant)

- *Regimens*: TC (docetaxel + cyclophosphamide), AC-T (doxorubicin + cyclophosphamide → paclitaxel)

- *Per cycle cost*: $420–$780, depending on drug selection and dose intensity

• •Biomarker & Monitoring Labs (per test)

- IHC (ER/PR/HER2): $45–$65

- FISH for HER2: $180–$220 - Oncotype DX (21-gene assay): $1,450–$1,750 - ctDNA monitoring (e.g., Guardant360®): $820–$980/test

Surgical / Procedural Options

*Eligibility*: Clinically operable disease (T1–T4aN0–N2, no distant metastasis); cardiac/pulmonary clearance required.

• •Lumpectomy + Sentinel Lymph Node Biopsy (SLNB)

- *Pre-op workup (CBC, LFTs, ECG, chest X-ray, breast ultrasound/MRI)*: $210–$330

- *Procedure fee*: $2,400–$3,100 - *Intraoperative pathology (frozen section)*: $180–$240

• •Mastectomy (Simple or Skin-Sparing)

- *Pre-op workup (same as above)*: $210–$330

- *Procedure fee*: $3,600–$4,900 - *Immediate reconstruction (implant-based)*: $5,200–$7,400 (separate billing)

• •Axillary Lymph Node Dissection (ALND)

- *If SLNB positive or clinically node-positive*: $1,900–$2,500

Special/Complex Condition Management

• •Metastatic Disease (Bone/Liver/Lung):

- Bone-targeted therapy (zoledronic acid IV monthly): $110–$140/dose

- Liver-directed radioembolization (Y-90): $8,200–$10,500/session

• •Triple-Negative Breast Cancer (TNBC):

- Neoadjuvant pembrolizumab + chemo: $6,300–$7,800/cycle (4 cycles)

• •BRCA1/2 Mutation Carriers:

- Risk-reducing contralateral mastectomy: $3,400–$4,600

Quick Selection Guide

• •Early-stage, ER+/HER2−, budget-conscious (<$2,000): Lumpectomy + endocrine therapy (generic tamoxifen) + standard adjuvant radiation
• •Young premenopausal, high-grade, BRCA+: Mastectomy + bilateral risk-reducing surgery + ovarian suppression + CDK4/6 inhibitor (palbociclib: $1,900/month)
• •Locally advanced, HER2+: Neoadjuvant pertuzumab/trastuzumab/docetaxel → surgery → adjuvant trastuzumab → extended neratinib ($2,300/month × 1 year)
• •Elderly (>75), significant comorbidities: Endocrine monotherapy ± palliative radiation ($1,100–$1,600 total) — avoid chemotherapy/surgery unless symptomatic progression